How Much Does Basaglar Cost With Medicare?
Basaglar (Insulin Glargine (biosimilar)) costs an average of $130 per Medicare Part D claim, with total Medicare spending of $845.0M in the latest year. No generic alternative is currently available.
Key Facts: Basaglar Cost
- Medicare Part D avg
- $130/claim
- Likely Part D tier
- Tier 2 (preferred brand)
- Annual cost/patient
- $1,174
- Generic available
- No
- Manufacturer
- Eli Lilly
- Treats
- Diabetes
- Patent expires
- 2028-12-16
- YoY price change
- -12.1%
Source: CMS Medicare Part D Spending Dashboard. Tier placement inferred from typical formulary norms — confirm with your specific Part D plan.
Basaglar Medicare Coverage & Out-of-Pocket Cost
Basaglar is covered under Medicare Part D, with the program paying an average of $130 per prescription fill. Basaglar typically falls on Tier 2 (preferred brand) of standard Part D formularies. Typical copay: $25-$50 per fill on most Medicare Part D plans.
Your actual out-of-pocket cost depends on three factors: (1) formulary tier — your plan's specific placement; (2) deductible status — most plans require you to meet up to a $590 deductible (2025) before copays kick in; (3) coverage phase — initial coverage, then the donut hole was eliminated in 2025, replaced by a hard $2,000 annual out-of-pocket cap under the Inflation Reduction Act. Once you hit $2,000 in true out-of-pocket spending, the rest of your Part D drugs are free for the year.
No generic is currently available for Basaglar. Medicare beneficiaries cannot use manufacturer copay cards (anti-kickback statute prohibits them for federal program enrollees), but charity foundations such as the PAN Foundation, NeedyMeds, and the HealthWell Foundation offer copay grants for many diabetes drugs. The Medicare Extra Help (LIS) program also reduces Part D costs to near-zero for income-qualified beneficiaries (under 150% of the federal poverty level).
For cash-pay or commercial insurance scenarios, compare prices using GoodRx, SingleCare, or Cost Plus Drugs before filling — discount-program prices sometimes beat Part D copays for lower-cost generics.
Basaglar is manufactured by Eli Lilly and prescribed primarily for Diabetes. In the most recent Medicare Part D data, 6,480,000 claims were filed for 720,000 unique beneficiaries, at an average cost of $130 per claim. Average annual cost per beneficiary is $1,174.
Year over year, Medicare spending on Basaglar has decreased by -12.1%. No generic substitute is available, so the brand-name price reflects the full market cost. Its patent expires 2028-12-16.
Basaglar belongs to the Diabetes Medications class. Metformin reduces liver glucose production ($4/month generic). GLP-1 agonists (Ozempic, Trulicity) mimic gut hormones to stimulate insulin release and reduce appetite. SGLT2 inhibitors (Jardiance, Farxiga) block glucose reabsorption in kidneys. DPP-4 inhibitors (Januvia) enhance the body's own incretin hormones. Insulin directly replaces what the body can't produce.
Key Data
| Metric | Value |
|---|---|
| Avg Cost Per Claim | $130 |
| Total Medicare Spending | $845.0M |
| Total Claims | 6,480,000 |
| Beneficiaries | 720,000 |
| Generic Available | No |
| Year-Over-Year Change | -12.1% |
Other Drugs for Diabetes
Frequently Asked Questions
Medicare Part D pays an average of $130 per claim for Basaglar. Basaglar is typically placed on Tier 2 (preferred brand) of standard Part D formularies. Typical copay: $25-$50 per fill on most Medicare Part D plans. As of 2025, total annual out-of-pocket on Part D is capped at $2,000 under the Inflation Reduction Act.
Yes. Basaglar appears in Medicare Part D claims data, with 720,000 beneficiaries filling 6,480,000 prescriptions in the latest year. Specific coverage depends on your plan's formulary — call the number on your insurance card or check the plan's Summary of Benefits to confirm prior authorization, step therapy, or quantity limit requirements.
Basaglar (Insulin Glargine (biosimilar)) costs an average of $130 per Medicare Part D claim, with total Medicare spending of $845.0M in the latest year. No generic alternative is currently available.
No. As of the latest FDA Orange Book data, there is no generic version of Basaglar (Insulin Glargine (biosimilar)). Patent protection extends until 2028-12-16, after which generics may enter the market.
Medicare beneficiaries cannot use manufacturer copay cards (anti-kickback statute), but several options exist: (1) Apply to charity copay foundations like the PAN Foundation, NeedyMeds, HealthWell Foundation, or Patient Advocate Foundation — many cover diabetes drugs; (2) Ask your prescriber about therapeutic alternatives in the same drug class that may be on a lower tier; (3) For some drugs, paying cash via GoodRx or Cost Plus Drugs can beat your Medicare copay — always compare before filling; (4) If your income is below 150% of the federal poverty level, you may qualify for the Medicare Extra Help (Low-Income Subsidy) program, which reduces Part D costs to near-zero.
Basaglar is manufactured by Eli Lilly. The FDA application number is BLA205692.
Basaglar (Insulin Glargine (biosimilar)) is primarily prescribed for Diabetes.
Medicare Part D spending on Basaglar has decreased -12.1% year over year. Total program spending reached $845.0M in the latest reporting year.
Basaglar (Insulin Glargine (biosimilar)) costs an average of $130 per Medicare Part D claim, with total Medicare spending of $845.0M in the latest year. No generic alternative is currently available.
This answer pulls from CMS Medicare Part D Drug Spending data, the authoritative federal source for U.S. Medicare prescription-drug pricing. The headline number above is the direct answer; what follows is the additional context most readers need to use the answer for a real decision rather than just a fact lookup.
A practical caveat: the headline answer above reflects the most recent CMS Medicare Part D Drug Spending data vintage; underlying data is often revised for months after first publication, and the right reference for any specific decision is whichever vintage is current at the time of the decision. The as-of date is stamped on every page.
Source: CMS Medicare Part D Spending, 2026.